Breast Cancer Clinical Research Studies

A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma

Status: Enrolling
Updated: 11/14/2015

Foundation for Cancer Research and Education

mi

from

Phoenix, AZ

3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection

A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma

Status: Enrolling
Updated: 11/14/2015

CCOP - Marshfield Clinic Research Foundation

mi

from

Marshfield, WI

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

Sibley Memorial Hospital

mi

from

Washington,

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

University of Hawaii Cancer Center

mi

from

Honolulu, HI

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

MedStar Union Memorial Hospital

mi

from

Baltimore, MD

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

MedStar Good Samaritan Hospital Cancer Center

mi

from

Baltimore, MD

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

Walter Reed National Military Medical Center

mi

from

Bethesda, MD

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

Wake Forest University Comprehensive Cancer Center

mi

from

Winston-Salem, NC

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

Carl R. Darnall Army Medical Center

mi

from

Fort Hood, TX

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

San Antonio Army Medical Center

mi

from

Fort Sam Houston, TX

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

University of Texas M.D. Anderson Cancer Center

mi

from

Houston, TX

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

STOH Clinical Research

mi

from

San Antonio, TX

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

Madigan Army Medical Center - Tacoma

mi

from

Tacoma, WA

Vaccine Therapy in Treating Patients With Breast Cancer

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients

Status: Enrolling
Updated: 11/16/2015

Landstuhl Regional Medical Center

mi

from

Landstuhl,